올릭스
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | KRW 3.7bn | KRW 9.3bn | KRW 17.1bn | KRW 5.7bn | KRW 14.7bn | KRW |
| Operating income | -KRW 25.4bn | -KRW 22.4bn | -KRW 18.2bn | -KRW 30.9bn | -KRW 30.0bn | KRW |
| Net income | -KRW 29.7bn | -KRW 19.5bn | -KRW 19.1bn | -KRW 40.7bn | -KRW 15.7bn | KRW |
| Total equity | KRW 18.5bn | KRW 65.9bn | KRW 49.9bn | KRW 17.8bn | KRW 149.4bn | KRW |
| Total liabilities | KRW 67.3bn | KRW 66.4bn | KRW 52.5bn | KRW 52.8bn | KRW 45.3bn | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 363.18 | 100.82 | 105.28 | 295.69 | 30.32 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Show raw values
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | 3,674,356,765 | 9,320,323,645 | 17,064,275,446 | 5,677,151,911 | 14,666,854,279 | KRW |
| Operating income | -25,423,672,146 | -22,375,609,579 | -18,185,342,175 | -30,918,594,163 | -29,972,430,134 | KRW |
| Net income | -29,714,663,862 | -19,495,352,386 | -19,101,696,120 | -40,658,699,598 | -15,742,651,455 | KRW |
| Total equity | 18,521,114,315 | 65,907,391,784 | 49,854,507,616 | 17,848,889,855 | 149,379,304,628 | KRW |
| Total liabilities | 67,264,591,995 | 66,448,925,303 | 52,489,094,571 | 52,776,577,150 | 45,287,290,658 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준) | 363.18 | 100.82 | 105.28 | 295.69 | 30.32 | % |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 91,000
- 80%
- 81,539.34 ~ 104,203.47
- 90%
- 78,634.74 ~ 108,014.73
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-10-14Filing title as filed기업설명회(IR)개최 original ↗Source: dart_disclosure
- 2026-10-12Filing title as filed투자판단관련주요경영사항 (임상시험계획 승인 신청 반려) original ↗Source: dart_disclosure
- 2026-10-08Filing title as filed[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (안드로겐성 탈모가 있는 건강한 남성을 대상으로 OLX72021의 안전성과 유효성을 평가하기 위한 다기관, 무작위 배정, 이중 눈가림, 위약 대조, 다중 상승 용량 제1b/2a상 임상시험 계획 승인) original ↗Source: dart_disclosure
- 2026-10-06Filing title as filed기업설명회(IR)개최 original ↗Source: dart_disclosure
- 2026-09-30Filing title as filed[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) original ↗Source: dart_disclosure
- 2026-09-16Filing title as filed투자판단관련주요경영사항(임상시험계획승인신청) original ↗Source: dart_disclosure
- 2026-09-08Filing title as filed[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (안드로겐성 탈모가 있는 건강한 남성을 대상으로 OLX72021의 안전성과 유효성을 평가하기 위한 다기관, 무작위 배정, 이중 눈가림, 위약 대조, 다중 상승 용량 제1b/2a상 임상시험 계획 승인신청) original ↗Source: dart_disclosure
- 2026-09-01Filing title as filed전환주식의전환청구권행사 (전환우선주) original ↗Source: dart_disclosure
- 2026-09-01Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
- 2026-08-31Filing title as filed전환주식의전환청구권행사 (전환우선주) original ↗Source: dart_disclosure
- 2026-08-28Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-21Filing title as filed투자판단관련주요경영사항 (Hansoh와의 공동연구 및 염기서열 이전 계약 체결) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-08-12Filing title as filed[기재정정]주식매수선택권부여에관한신고 original ↗Source: dart_disclosure
- 2026-08-12Filing title as filed[기재정정]주식매수선택권부여에관한신고 original ↗Source: dart_disclosure
- 2026-08-12Filing title as filed[기재정정]주식매수선택권부여에관한신고 original ↗Source: dart_disclosure
- 2026-08-10Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
- 2026-08-04Filing title as filed[기재정정]투자판단관련주요경영사항 (중추신경계 전달체 기술평가 및 기술도입 옵션 계약 체결) original ↗Source: dart_disclosure
- 2026-08-03Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
- 2026-07-30Filing title as filed임시주주총회결과 original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…